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Context: McCune Albright syndrome (MAS) is a clinical association of endocrine and nonendocrine
anomalies caused by postzygotic mutation of the GNAS1 gene, leading to somatic activation of the
stimulatory -subunit of G protein (Gs). Important advances have been made recently in describ-
ing pathological characteristics of many MAS-affected tissues, particularly pituitary, testicular, and
adrenal disease. Other rarer disease related features are emerging.
Objective: The objective of the investigation was to study the pathological and genetic findings of
MAS on a tissue-by-tissue basis in classically and nonclassically affected tissues.
Design: This was a comprehensive autopsy and genetic analysis.
Setting: The study was conducted at a tertiary referral university hospital.
Patients: An adult male patient with MAS and severe disease burden including gigantism was the
subject of the study.
Intervention(s): Interventions included clinical, hormonal, and radiographic studies and gross and
microscopic pathology analyses, conventional PCR, and droplet digital PCR analyses of affected and
nonaffected tissues.
Main Outcome Measure: Pathological findings and the presence of GNAS1 mutations were measured.
Results: The patient was diagnosed with MAS syndrome at 6 years of age based on the association
of café-au-lait spots and radiological signs of polyostotic fibrous dysplasia. Gigantism developed
and hyperprolactinemia, hypogonadotropic hypogonadism, and hyperparathyroidism were diag-
nosed throughout the adult period. The patient died at the age of 39 years from a pulmonary
embolism. A detailed study revealed mosaiscism for the p.R201C GNAS1 mutation distributed
across many endocrine and nonendocrine tissues. These genetically implicated tissues included rare
or previously undescribed disease associations including primary hyperparathyroidism and hyper-
plasia of the thymus and endocrine pancreas.
Conclusions: This comprehensive pathological study of a single patient highlights the complex
clinical profile of MAS and illustrates important advances in understanding the characteristics of
somatic GNAS1-related pathology across a wide range of affected organs. (J Clin Endocrinol Metab
99: E2029–E2038, 2014)
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McCune Albright syndrome (MAS) is a very rare spo-radic genetic disorder that comprises a triad of
polyostotic fibrous dysplasia (FD), café-au-lait skin pig-
mentation, and precocious puberty (1, 2). MAS can affect
a wide range of tissues beyond the classical triad, including
endocrine organs (pituitary, thyroid, and adrenals), the
gastrointestinal tract, and others (3, 4). MAS is caused by
somatic missense mutations of the GNAS1 gene, which
lead to constitutional activation of Gs protein, raised
cAMP, and increased cellular activity and growth (5–7). In
MAS the GNAS1 mutation is believed to occur postzy-
gotically, leading to mosaiscism for mutation-bearing cells
and hence a variable pattern in the variety and extent of
affected tissues. The burden of disease in MAS varies sig-
nificantly, and partial or incomplete forms of MAS have
been described (8). Craniofacial FD, in particular, can
vary widely in severity from asymptomatic to severe dis-
figurement and functional impairment. Craniofacial FD
may be severe in MAS patients with pituitary somatotrope
hyperfunction causing GH excess (9). Given the rarity of
MAS and the lack of an animal disease model, the clinical
epidemiology of MAS is only now being comprehensively
elucidated in long-term collaborative efforts that have de-
fined important features like gonadal pathology in males
and the management of MAS-related pituitary disease (9,
10).
Few comprehensive anatomopathological studies have
been published in subjects with MAS. We describe a pa-
tient with MAS with a heavy disease burden comprising
deforming craniofacial and axial skeletal FD and gigan-
tism that contributed to his early death. A comprehensive
pathological and genetic study at postmortem provided a
unique insight into the pathology and genetics of a variety of
MAS-related abnormalities, both classical and rarely de-
scribed/novel, underlining the multiple major and minor dis-
ease manifestations in MAS.
Materials and Methods
Case history
A 35-year-old male was referred to our clinic for evaluation
and monitoring. He had been diagnosed with MAS at 6 years of
age based on the presence of café-au-lait macules (lower back and
right arm) and radiological signs of polyostotic FD in addition to
precocious puberty. At original presentation he was well above
the 97th centile for height (135 cm) and weight (29 kg) (Figure
1). He had associated facial asymmetry due to marked right-
sided skull base expansion. Extensive upper and lower limb bony
involvement was present. The cranial nerve examination re-
vealed a mild loss of visual acuity in the right eye and an im-
pingement on the upper nasal field of the left eye. There was
hearing loss on the right ear. The skeletal pathology progressed
rapidly through childhood and adolescence, becoming particu-
larly severe in the vertebrae, hips (right sided osteosynthesis re-
quired), and cranial bones. These latter changes led to the dis-
placement of the left eye laterally and development of marked
asymmetry of the face and jaw. The hip pathology progressed,
with a right-sided coxa vara developing, and at the age of 13
years, a right-sided osteosynthesis of the hip was performed.
Aged 11 years, the patient’s pubertal development was P3,
G3, A1; gonadal, thyroid and adrenal hormone profiles were
normal. The patient’s height increased and he reached 186 cm by
the age of 13 years. Imaging of the sella revealed no enlargement
or evidence of a pituitary tumor. Basal GH levels were consis-
tently elevated (10–20 ng/mL; normal  3 ng/mL), with a par-
adoxical increase after an oral glucose load. He also had mod-
erate hyperprolactinemia at about 2.5 times the upper limit of
normal. Treatment with bromocriptine had no noticeable effect
on GH levels (somatostatin analogs were unavailable at that time
and neurosurgery was declined). Radiological changes in the
distal phalanges were typical of the deformation seen in acro-
megaly. The subsequent evolution was marked by progressive
vertical growth reaching a final adult height of 205 cm, further
coarsening of facial features, acral growth, multiple bone defor-
mities, and worsening craniofacial FD (Figure 2), with patho-
logical fractures within the FD affected regions (right and left
femoral neck, left femoral shaft, and left elbow), with bilateral
hip prostheses required and scoliosis that required surgery. Bio-
chemically and hormonally the patient exhibited persistent GH
excess with concomitant hyperprolactinemia, which was treated
with a long-acting somatostatin analog, although GH and IGF-1
remained elevated.
Figure 1. The patient’s original pediatric growth chart shows height
and weight above the 97th centile at presentation, when aged 6 years.
His gigantism progressed throughout childhood in parallel with the
development of marked craniofacial FD and hip disfigurement, and at
the age of 12 years, his height was already 176 cm.
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By the age of 30 years, the patient had developed hypogo-
nadotropic hypogonadism (LH and FSH below the limit of quan-
titation, T 2.7 nM). Subsequently, primary hyperparathyroidism
was diagnosed [total calcium: 10.6 mg/dL (upper limit of nor-
mal: 10.4 mg/dL); PTH: 104 pg/mL], which was associated with
symptomatic nephrolithiasis of the right kidney. Thyroid and
adrenal function measures were normal. By that time, brain mag-
netic resonance imaging (MRI) showed a normally proportioned
pituitary gland that was accompanied by a large inferior sellar
cystic lesion. There was profound facial, cranial, and cervical
vertebral deformity, with the FD causing marked displacement
of the cerebral parenchyma as illustrated in Figure 3 (see also
video in Supplemental Figure 1, A and B). He was completely
blind in the left eye. Addition of cabergoline to that of lanreotide
Autogel successfully controlled IGF-1 (but not GH) and hyper-
prolactinemia. The patient presented to the emergency room
with a severe iron-deficiency anemia of a suspected gastrointes-
tinal source; endoscopy showedaBarrett’s esophagusandpolyps
in the pylorus of the stomach (although
no active bleeding source). Megacolon
was also diagnosed.
The patient remained stable for 4
years after presentation to our depart-
ment. At the age of 39 years, he collapsed
and fell at home, which was associated
with medullary compression and quad-
riplegia, and he died due to a cardiore-
spiratory arrest. On autopsy, a pulmo-
nary embolism with lung infarction was
determined as the primary cause of
death. Particular attention was paid to
investigating the role of MAS at a tissue




Tissue fragments obtained from or-
gans were fixed in 10% buffered forma-
lin and embedded in paraffin; 5-m-thin
sections were then cut and stained with
hematoxylin and eosin, periodic acid-Schiff reaction, and Foot’s
stain for light microscopy. An immunohistochemical analysis
was performed on deparaffinized and dehydrated 5-m tissue
sections using the Dako EnVision system and the peroxidase/
diethylaminobenzidene detection kit (Dako), according to the
manufacturer’s instructions. Immunostaining for chromogranin
A, synatophysin, and inhibin was performed using monoclonal
antibodies (Dako)diluted1:600,1:2, and1:150, respectively; for
CD56 staining the monoclonal antibody from Novocastra was
used after 1:150 dilution. Positive control sections were prepared
from lung carcinoid tumor and normal testis for inhibin. Neg-
ative controls were obtained by replacing the primary antibody
with Tris-buffered saline.
Genetic studies
DNA was obtained from formalin-fixed tissues and paraffin-
embedded fragments after digestion with proteinase K using
commercially available kits (QIAGEN)
as previously described (11). After puri-
fication of proteolysis residues, the final
samples of DNA were washed with 70%
ethanol and quantified with an UV spec-
trophotometer. Prior to PCR amplifica-
tion, DNA samples were incubated for 1
hour at 37°C in the presence of BSA (12).
Mutation detection was performed
by standard PCR amplification followed
by sequencing of the GNAS1 gene. Se-
lective enrichment of the mutant allele
was achieved by specific endonuclease
digestion of the PCR product from the
normal gene, as described previously
(13, 14). Each test included a control
sample that consisted of DNA heterozy-
gous for the p.R201C mutation that was
diluted 1:10 with wild-type DNA. It was
detected as wild type after a single round
of PCR but as heterozygous after the en-
Figure 2. Radiological images demonstrating severe craniofacial FD in a MAS patient with
gigantism. Plain skull radiographs of the patient at the age of 30 years show massive bone
overgrowth affecting the entire skull, particularly the occipital bones, in addition to deforming
enlargement of the mandible.
Figure 3. Coronal (A) and axial (B) MRI features in the MAS patient demonstrating profound
craniofacial FD and related impingement of the brain and displacement of the optic nerves and eyes.
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richment procedure. This led us conclude that the mutant allele
is present in at least 10% of the cells from tissues found to be
heterozygous after enrichment. Using numerical PCR (15) in
droplets (16) (ddPCR; Bio-Rad Laboratories), we measured the
proportion of GNAS1 p.R201C mutation in DNA samples. Five
microliters of DNA were used in the presence of ddPCR super-
mix for Probes (Bio-Rad Laboratories). With ddPCR, the sample
is dispensed so that each DNA molecule is localized in a distinct
reaction chamber. In contrast to conventional PCR, ddPCR scat-
ters the reaction in a large number of partitions studied individ-
ually. Sample partitioning allows the counting of molecules ac-
cording a Poisson’s distribution. Consequently, each reaction
chamber contains either zero or one molecule, namely a negative
or a positive reaction, respectively. After PCR amplification, nu-
cleic acids can be quantified by counting the positive reactions.
The number of positive tests related to the total number of anal-
yses performed provides an absolute quantification. ddPCR per-
mits the reading of 15 000–16 000 droplets per sample. Primers
and hydrolysis probes sequences together with ddPCR condi-
tions are available on request.
Results
At autopsy there were typical features of acrogigantism,
and the patient measured 200 cm in length. Extensive ver-
tebral scoliosis, external flexion of the right leg, and sig-
nificant lower limb muscle atrophy were also observed.
Thickening of the frontal bone and a large mandibular
tumor contributed to the skull deformity. Café-au-lait le-
sions were present in the right lower thoracic region and
on the right arm.
Skeletal system
The pathological findings in the skeleton consisted of cor-
tical hyperplasia, cysts secondary to bone destruction in the
medulla and lesions of fibrous dysplasia presenting either as
diffuse hyperplasia or bone tumors.
Long bones exhibited increased corti-
cal thickness, but the density was de-
creased in areas with multiple medul-
lar cysts containing fibrous tissue. The
right humerus, femur, and most of the
right side of the skull displayed pseu-
dotumoral features with severe and
diffuse expansion of the medulla.
Lightmicroscopyrevealedscleroticar-
eas, areas of proliferation with a fibro-
dysplasic appearance, and necrotic
fields with hemorrhage.
Craniofacial fibrous dysplasia
The full extent of the skull abnor-
malities in this patient are illustrated
in Figure 2, with simple radiographs
demonstrating the mandibular dis-
tortion due to a bone tumor. The
craniofacial FD led to marked compression of the brain
and spinal cord, with these elements echoing the previ-
ously established radiological findings (Figure 3). These
changes are shown in situ in Figure 4A. A large, well-
delineated tumor was found on the right side of the man-
dible. It had a heterogeneous histological structure with
fibrous and dense bone tissue predominating in the central
area, whereas the periphery displayed regions of neovas-
cularization and metaplastic bone formation (Figure 4B).
Central nervous system
Both cerebral hemispheres presented flattening and de-
formities of the frontoorbital region due to bone compres-
sion (Figure 3). Except for diffuse cerebral edema, there
were no macroscopic or microscopic brain or spinal cord
lesions.
Skin
The epidermal structure and thickness were normal.
The superficial and deep dermis was hyperplastic with a
concentric and lamellar distribution of collagen bundles
around skin appendages. Collagen bundles appeared
broad and densely packed using Masson’s trichrome stain
and orcein staining showed dystrophic elastic fibers with
irregular size and focal fragmentation. On immunohisto-
chemistry, factor XIIIa positive dermal dendrocytes type 1
were scattered, globular, and of small size.
Endocrine system
Pituitary
The pituitary was enlarged and occupied an enlarged
sella turcica. There was a large adenoma that had poor
Figure 4. Pathological findings in tissues studied postmortem. Panel A illustrates the marked
thickening of the skull due to craniofacial FD, while Panel B shows light microscopy of an
affected region of bone pathology. Panel C shows pituitary gland with positive immunostaining
for GH (brown) of an adenoma against a background of diffuse somatotrope hyperplasia.
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reticulin structure, and it stained strongly for GH (100%)
and LH (10%–15%), whereas occasional cells were
ACTH positive (Figure 4C). Prolactin staining was not
found in the adenoma. The parenchyma surrounding the
nodule exhibited diffuse somatotrope hyperplasia with
enlarged trabeculae and stained for the different pituitary
hormones, with the notable exception of prolactin.
Testis
The testes were of normal volume; macroscopically the
tunica albuginea was thickened and there was a tunica
vaginalis cyst on the right side. Microscopically, there was
generalized atrophy of seminiferous tubes with an asso-
ciated thickening of the basal membrane (Figure 5A). Mul-
tiple dark red/brown cysts were found close to the rete
testis. These cysts were comprised of nodular Leydig cell
hyperplasia; microcalcifications were also visible on light
microscopy (Figure 5A). The hyperplastic cells stained
positive for inhibin and the cytoplasm contained Reinke’s
crystalloid. The right testis contained a small area of nor-
mal parenchyma in which spermatogenesis was present
(Figure 5, B and C).
Thyroid
The thyroid examination revealed homogenous multi-
nodular goiter. Light microscopy displayed glandular hy-
peractivity with areas of colloidal pseudonodules.
Parathyroids
All four parathyroid glands were enlarged, which was
shown to be due to nodular hyperplasia under microscopic
examination (Figure 6A).
Endocrine pancreas
Hypertrophic and hyperplasic Langerhans islets were
visualized in the tail of the pancreas (Figure 6B).
Adrenals
The adrenal glands exhibited bilateral cortical mi-
cronodular hyperplasia, as shown in Figure 6C.
Cardiovascular and respiratory systems
The heart was hypertrophic in appearance and hyper-
trophic cardiomegaly was confirmed histologically. No
significant atherosclerosis was observed. Histological
analysis of the right lung revealed recent infarction and
edema caused by numerous microthrombi in the small
vessels.
Gastrointestinal system
Three pseudopolyps with normal, nonhamartomatous
(17), histological structure were present in the pylorus of
the stomach. The liver was enlarged mainly due to con-
gestion and cholestasis. Chronic pancreatitis with micro-
lithiases was evident in the periphery of the head of the
pancreas. Interestingly, islet cell hyperplasia was present.
Immunohistochemical analysis did not detect increased
population of endocrine cells in the lining of the stomach,
duodenum and ileocecal region.
Figure 5. Panel A shows the testis, stained with hematoxylin and
eosin (25). Large nodule of Leydig cell hyperplasia (1) with multiple
microliths (2) and residual atrophic seminiferous tubes (3). Panel B
shows the testis stained with hematoxylin and eosin (100).
Seminiferous tubes with preserved complete spermatogenesis (1) are
shown. Nodule of hyperplastic Leydig cells (2) is also shown. Panel C
shows Leydig cell hyperplastic nodule at 250 magnification with
Reinke’s crystalloid (arrows).
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Urinary system
Both kidneys were enlarged with signs of chronic pye-
lonephritis and medullary calcifications on light micros-
copy. No pathological findings were present in the
prostate.
Immune system
The spleen was enlarged but microscopically normal.
Remarkably for an adult patient, the thymus was intact
and presented no signs of fat involution or atrophy (Figure
6D).
Mutation analysis
Paraffin-embedded and formalin-fixed samples from
different organs were available for genetic study (Table 1).
In pituitary adenoma and hyperplasia samples, DNA am-
plification was not possible due to DNA degradation.
Heterozygous p.R201C mutation of the GNAS1 gene was
identified in several tumoral or pathologically abnormal
samples, such as bone tumors and thyroid, parathyroid,
thymus, and testis tissues. Pigmented skin was wild type,
whereas apparently normal unpigmented skin bore the
GNAS1 mutation. Interestingly, tissues that are atypical-
ly/rarely involved in the MAS phenotype but that were
pathologically affected in this case such as the pancreas,
thymus, thyroid, and adrenals also
had the GNAS1 mutation in a mo-
saic distribution.
Discussion
MAS is a distinctive form of endo-
crine and nonendocrine neoplasia
caused by a postzygotic mutation of
the GNAS1 gene, with affected cells
being distributed in a mosaic pat-
tern. This unique molecular patho-
physiology leads to variability in the
clinical expression and severity of
disease features (3, 18, 19). Study of
MAS differs from that of other en-
docrine neoplasia syndromes due to
the lack of a robust animal model,
meaning that the molecular pathol-
ogy of the disease at an organ level is
derived from painstaking study of
clinical case collections. The current
case underlines the importance of
considering the myriad of possibly
affected tissues. Additionally, this
case highlights that in MAS patients,
the disease impact might extend to
atypical or rarely described sites such as the thymus, para-
thyroids, and pancreas. Indeed, in all three of these tissues,
the use of newer PCR techniques (ddPCR), allowed us to
demonstrate the presence of the GNAS1 mutation in all
three of these pathological tissues from this patient. In our
patient the GNAS1 mutation was identified in all but one
affected organ and a mosaic distribution was confirmed.
In the pituitary adenoma and hyperplasia, it was impos-
sible to demonstrate the GNAS1 mutation using either
conventional or advanced PCR techniques because the
DNA was too heavily degraded. Previously, conventional
PCR techniques have failed to show GNAS1 mutations in
MAS patients despite diagnostic clinical features (14); we
suggest that the use of techniques such as ddPCR could im-
prove genetic diagnosis rates in suspected MAS patients.
Apart from the classical bone and skin involvement,
our patient exhibited multiple endocrine abnormalities.
The patient’s most important endocrine abnormality was
acrogigantism due to somatotrope hyperfunction and pro-
longed GH and IGF-1 excess (20). Acromegaly or gigan-
tism occurs in a minority of cases of MAS, and recently
Boyce et al (21) reported 26 of 129 (20.2%) of the Na-
tional Institutes of Health (NIH) MAS cohort had GH
excess, which confirms original estimates (22). Acromeg-
Figure 6. Panel A shows parathyroid gland stained with hematoxylin and eosin (25)
illustrating a region of nodular hyperplasia. Panel B shows pancreas stained with hematoxylin and
eosin (25) with extensive hyperplasia of the islets of Langerhans and associated calcifications.
Panel C shows micronodular hyperplasia of the adrenal gland on hematoxylin and eosin stain
(25). Panel D shows thymus gland stained with hematoxylin and eosin (25) and persistence of
thymic tissue (1), Hassall’s corpuscles (2) and epithelial hyperplasia.
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aly in MAS differs significantly from sporadic causes be-
cause pituitary abnormalities on MRI are often not pres-
ent or are marginal despite advanced disease. In the
current patient, multiple MRIs reported no abnormality of
the sella and no adenoma. However, on autopsy a soma-
totrope adenoma surrounded by diffuse hyperplasia was
discovered.Thisunderlines the recent conclusionsofVort-
meyer et al (9) that pituitary disease in MAS is a diffuse and
varied pathology. The disconnect between imaging and
direct visualization may be due to deformation by FD in-
terfering with sellar imaging. The pituitary in the current
case exhibited the typical somatotrope hyperplasia that
constitutes the primary abnormality in acromegaly in
MAS. Some patients may have somatomammotrope hy-
perplasia; in the current case, no prolactin staining was
seen, although this may have been due to chronic caber-
goline treatment. The craniofacial FD in this case contin-
ued to advance during the patient’s third and fourth de-
cade, with deformity leading to monocular blindness and
hearing impairment.
The issue of craniofacial FD and GH excess in MAS has
received consistent attention (18, 22–26). The dramatic
craniofacial FD that developed in this adult patient (Fig-
ures 2–4) is in keeping with the harmful role of GH excess
on cranial bone pathology in MAS patients. Recent data
indicate that MAS patients with GH excess that have early
intervention (18 y of age) to control GH/IGF-1 have
decreased risk of optic neuropathy (21). Among 22 sub-
jects with significant somatotrope hyperfunction in the
NIH cohort, 15 had intervention before the age of 18 years
(early) and the other seven after the age of 18 years (late).
Notably the subjects with late intervention for GH control
had a significantly larger head circumference than the
early intervention or control MAS groups. This indicates
that earlier control of somatotrope axis hyperfunction can
slow the underlying FD growth and limit craniofacial dis-
tortion. This finding is echoed in the experience of the
current patient, who had late control of somatotrope axis
hyperfunction. In his case, control of GH excess was not
medically achievable in childhood/adolescence because
somatostatin analogs were not available. Current guide-
lines recommend that GH/IGF-1 control should be prior-
itized to potentially prevent worsening of craniofacial FD.
This is also to prevent the worsening of other conditions
like cardiac muscle dysfunction/cardiomyopathy, to
which both acromegaly and GNAS1 mutations can con-
tribute. Some patients respond well to long-acting soma-
tostatin analogs (27), but somatostatin analog resistance
has been reported, and in those cases GH receptor antag-
onist treatment (27, 28) or combined medical therapy (29)
can be successful.
Hyperprolactinemia has been associated with GH hy-
persecretion in most MAS patients (22) as well as in spo-
radic somatotrope tumors bearing the gsp oncogene (22,
30). The absence of prolactin on immunohistochemistry in
our case may be due to cabergoline treatment. Dopamine
agonists can help in controlling hyperprolactinemia, but
do not appear to provide significant benefit in GH/IGF-1
control. Radiotherapy in MAS is limited by concerns over
malignant transformation of fibrodysplastic bone when
radiotherapy is used (31). Surgery can be complicated be-
cause of not only the significant bone overgrowth and
anatomical distortion but also because acromegaly in
MAS is primarily due to somatotrope or somatomammo-
trope hyperplasia. Hence, adenoma resection may not be
curative or an adenoma may not be present. In intractable
cases, hypophysectomy has been suggested as a curative
option when all other avenues have been exhausted (9).
Table 1. Results from the Genetic Analysis of GNAS1
in Endocrine and Nonendocrine Tissues
Tissue Source
Tissue
























Bone tumor 2 Formalin
fixed
Wild type
Bone tumor 3 FFPE p.Arg201Cys heterozygous
(GA heterozygous)











Thyroid FFPE p.Arg201Cys heterozygous
(GA heterozygous)
Heart FFPE Wild type
Parathyroida FFPE p.Arg201Cys heterozygous
(GA heterozygous)
Thymusa FFPE p.Arg201Cys heterozygous
(GA heterozygous)
Testisa FFPE p.Arg201Cys heterozygous
(GA heterozygous)
Pituitary adenoma FFPE Unsuccessful
Pituitary hyperplasia FFPE Unsuccessful
Abbreviation: FFPE, formalin fixed, paraffin embedded.
a Using ddPCR (Bio-Rad Laboratories).
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Peripheral precocious puberty is one of the hallmarks of
MAS and was the main endocrine abnormality that led to
the recognition of the disease in the 1930s (1, 2). It has a
high prevalence in females with MAS, possibly because
both granulosa and theca cell are steroidogenically com-
petent and subject to activation. In the testes, the Leydig
cells must carry the activating mutation to trigger preco-
cious androgen synthesis (32, 33). Sertoli cell-only muta-
tions may be responsible for testicular enlargement with-
out signs of peripheral hyperandrogenism (34, 35). Leydig
cell hyperplasia and focal spermatogenesis have been de-
scribed in MAS for many years (5), and testicular micro-
lithiasis was proposed as an additional pathological
marker in males (36). The testicular phenotype in MAS has
recently been elucidated in the clinical setting by Boyce et
al (10) in 54 males from the NIH cohort. They confirmed
that testicular ultrasound abnormalities were present in
81% of cases, with hyperechoic lesions and testicular het-
erogeneity in 45%–47% of cases. Bilateral disease oc-
curred in 75%, and 44% had macroorchidism, again usu-
ally bilaterally. Microlithiasis and/or focal calcification
were also characterized as occurring in 30% and 10% of
cases, respectively. On pathological examination of sur-
gical tissue (orchiectomy, biopsy, or autopsy material),
Leydig cell hyperplasia was found in seven of eight cases
(87.5%), similar to the extensive disease in the current
case. The picture of sclerosis, localized Leydig cells hyper-
plasia, and microcalcifications in our case are therefore
typical of gonadal effects in an adult male MAS patient
(Reinke crystalloid was not previously noted to our
knowledge). Although dramatic gonadal changes occur in
most males with MAS, the longitudinal follow-up is en-
couraging, with testicular malignancy being rare in the
NIH cohort, and in the rare occasion in which testicular
cancer did occur, the long-term response to therapy was
good.
In the current case, the thymus showed no signs of the
involution that would normally be expected in an adult,
and the GNAS1 mutation was shown in the thymic tissue.
GH itself is recognized to have a regulatory role in thymic
tissue growth, and thymic hyperplasia has been reported
in acromegaly and growth hormone treatment (37–39).
Whether persistence of the thymus in this case was due to
a primary effect of MAS or secondary to GH hypersecre-
tion is uncertain and requires study in larger cohorts. A
similarly intriguing finding was that of primary hyper-
parathyroidism associated with parathyroid hyperplasia,
and again more advanced PCR techniques showed the
GNAS1 mutation to be present in the hyperplastic tissue.
Primary hyperparathyroidism has been reported only
once in the NIH cohort, so the addition of this genetically
confirmed case due to multiglandular parathyroid hyper-
plasia suggests that it may form a rare association in MAS
(3). A GNAS1 mutation was also detected in the thyroid
and adrenal glands as well as the pancreas, but, despite
being associated with hyperplasia or histological abnor-
malities (islet cell hyperplasia), they were not associated
with hormonal hypersecretion. The bilateral adrenal hy-
perplasia that was found at autopsy in the patient was
unaccompanied by clinical or other evidence of overt
Cushing’s syndrome during his lifetime. However, as re-
ported by Brown et al (40), Cushing’s syndrome in MAS
can arise and later resolve spontaneously, leaving adrenal
abnormalities and residual adrenal dysfunction. No spe-
cific tests were performed to identify such residual bio-
chemical abnormalities during the patient’s lifetime.
Variable disease burden in MAS may be explained by
mosaicism in the affected organs, low expression of the
mutant allele in some tissues (41), interfering molecular
mechanism such as the increase in phosphodiesterase ac-
tivity (5, 42, 43), or possibly due to variable cell specific
consequences of increased cAMP production. According
to interactions between MAPK and cAMP pathways, the
cAMP increase could induce cell proliferation or differ-
entiation, depending on particular cell phenotype (44).
Despite the widespread endocrine and nonendocrine pa-
thology in this case, no tumors of the exocrine pancreas or
hepatobiliary system were seen, confirming that such tu-
mors occur in a minority of MAS cases (32%) (45).
In conclusion, the present case study, which incorpo-
rated a comprehensive clinical, pathologic, and genetic
analysis of an adult male patient with MAS, underlines the
variable tissue-specific sensitivity to GNAS1 mutation in
humans and illustrates the current clinical understanding
of the consequences of disease activity and treatment of
this remarkably challenging disease.
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